The drug is indicated for the treatment of a number of infections, including adjunctive therapy in severe acne
Australia’s Mayne Pharma Group recently announced the launch of doxycycline monohydrate immediate release (IR) capsules (50mg, 75mg and 100mg) in the United States.
Doxycycline IR capsules are a generic alternative to Monodox, a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.
Mayne Pharma’s CEO Scott Richards said, “This launch will further broaden Mayne Pharma’s dermatology portfolio of branded and generic products. Mayne Pharma is committed to helping patients and physicians cost-effectively manage various skin conditions including acne and psoriasis.”
Mayne Pharma directly markets more than 55 products and has a growing pipeline of around 30 drug products targeting U.S. markets with IQVIA sales greater than $5 billion. According to IQVIA, annual U.S. sales of doxycycline IR capsules were approximately $30 million for the 12 months ending Jan. 31, 2018.
Doxycycline IR capsules are a generic alternative to Monodox, a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.
Mayne Pharma’s CEO Scott Richards said, “This launch will further broaden Mayne Pharma’s dermatology portfolio of branded and generic products. Mayne Pharma is committed to helping patients and physicians cost-effectively manage various skin conditions including acne and psoriasis.”
Mayne Pharma directly markets more than 55 products and has a growing pipeline of around 30 drug products targeting U.S. markets with IQVIA sales greater than $5 billion. According to IQVIA, annual U.S. sales of doxycycline IR capsules were approximately $30 million for the 12 months ending Jan. 31, 2018.
